Bexobrutideg | YesPress

Browse all tags

ceo2909 saas2415 ai1731 fintech1456 founder1251 b2b1079 b2b saas888 san francisco823 co-founder816 san-francisco799 y combinator769 startup734 machine learning665 enterprise software625 stanford603 series a590 venture capital577 biotech543 cybersecurity535 healthtech479 new york startup469 ai agents452 enterprise-software447 generative ai437 digital health434 agentic ai393 silicon-valley389 d2c386 silicon valley381 ecommerce379 machine-learning373 startup founder360 california351 entrepreneur350 new york347 edtech343 venture-capital340 climate tech328 newsletter321 mit302 proptech302 robotics294 y-combinator281 san francisco startup278 enterprise ai276 series b273 developer tools264 computer vision255 oncology252 open-source247 series-a244 harvard242 supply chain241 sustainability240 iot232 enterprise229 biotechnology224 compliance224 workflow automation223 telehealth217 founder ceo216 healthcare213 insurtech212 developer-tools211 blockchain210 devops208 medical devices206 series-b206 logistics199 forbes 30 under 30194 llm193 uc berkeley189 author188 generative-ai188 clean energy187 deep tech187 web3185 cloud184 a16z183 drug discovery182 b2c176 life sciences176 artificial intelligence175 no-code175 manufacturing174 payments170 general partner169 healthcare ai169 crm168 serial entrepreneur167 seed funding164 open source162 automation160 podcast160 hardware159 digital transformation158 unicorn158 marketplace152 predictive analytics152 infrastructure151

Often tagged with

targeted protein degradation1 biotech1 biopharmaceutical1 oncology1 autoimmune disease1 e3 ligase1 ubiquitin-proteasome system1 btk degrader1 drug discovery1 clinical-stage1 nasdaq nrix1 del-ai1 degrader antibody conjugates1 cbl-b inhibitor1

Tagged: bexobrutideg

1 result

Sort

Health · Ai · Enterprise

Nurix Therapeutics

Nurix Therapeutics is a clinical-stage biopharmaceutical company in San Francisco pioneering targeted protein degradation - medicines that destroy disease-causing proteins rather than merely blocking them. Built on its DELigase discovery engine that harnesses the cell's ubiquitin-proteasome system and DNA-encoded library screening, Nurix is advancing a pipeline of degraders and degrader antibody conjugates for cancer and autoimmune disease, led by the BTK degrader bexobrutideg (NX-5948). The company is partnered with Roche, Sanofi, Gilead, and Pfizer (via Seagen) and trades on Nasdaq under NRIX.

targeted protein degradation · biotechRead →